[ad_1]
- The initial data for Phase 1/2 is 63road American Society of Hematology (ASH) Annual Conference and Expo
- NEXI-002 is being used as a single agent to treat patients with relapsed/refractory multiple myeloma who have failed more than 3 lines of treatment in a Phase 1/2 study
Gaithersburg, Maryland, December 12, 2021 (Global News Service)–NexImmune, Inc. (NASDAQ:relation), a clinical-stage biotechnology company that develops a new immunotherapy method that aims to coordinate the targeted immune response by directing the function of antigen-specific T cells, today announced the preliminary 1 of the ongoing NEXI-002 research Phase 2 results, the patient-derived multi-antigen-specific CD8+ T cell therapy is used to treat patients with relapsed/refractory multiple myeloma who have failed more than 3 treatments. The low-dose NEXI-002 data published at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition showed promising safety and tolerability characteristics, as well as evidence of immunological and clinical activity.
Poster presentation:
title: Preliminary analysis of phase 1/2 study of NEXI-002 autologous multi-antigen-specific CD8+ T cells in the treatment of relapsed or refractory multiple myeloma (RRMM)
Abstract number: 2824
category: Poster display
author: Maung Myo Htut, MD, Juan C. Varela, MD, PhD, Vineetha Edavana, PhD, Emily Lu, PhD, Sojung Kim, PhD, Lauren Suarez, PhD, Mathias Oelke, PhD, Daniel Bednarik, PhD, Robert D. Knight, MD and Andrew King, MD
Appointment time: Sunday, December 12, 2021; poster hall business hours are 6-8 pm Eastern Standard Time
In this heavily preconditioned patient group (n=6, average 7.6 lines of previous treatment), clinical data show that NEXI-002 is well tolerated and has no dose-limiting toxicity (no CRS ≥3 or ICAS of any grade) . Biomarker data shows that NEXI-002 product candidate contains CD8+ antigen-specific T cells with key memory phenotypes, which can be detected in the peripheral blood and bone marrow of the individual receiving treatment after administration, and proliferate over time And continue to exist. In addition, TCR sequencing revealed that NEXI-002 product candidates contained CD8+ T cell clones, which were undetectable in the peripheral blood of baseline patients, and…
The full story can be found on Benzinga.com
[ad_2]
Source link
